MIC (Lipo-C with B12)

Also known as MIC (Lipo C with B12)

Variable multi-ingredient MIC/Lipo-C formulation · lot-specific B12-containing research mixture

Component-specific · Batch COACAS Confirm per batch COARUO
Batch COA
MOQ1 kit (10 vials) per SKU
Supplied formMulti-ingredient aqueous small-molecule formulation (non-peptide; no single molecular identity)
Lead timeConfirmed with quote
MIC (Lipo-C with B12) — Lot-specific aqueous solution; color may vary with the cobalamin form — confirm clarity, color and particulate limits on the released-lot COA
MIC (Lipo-C with B12) — Lot-specific aqueous solution; color may vary with the cobalamin form — confirm clarity, color and particulate limits on the released-lot COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Claims of fat mobilization, weight loss, energy, liver support or synergy with GLP-1 medicines are not supported by a direct trial of a defined MIC/Lipo-C plus B12 formulation
  • Choline, methionine, inositol, vitamin B12 and L-carnitine have established biochemical roles or indication-specific evidence, but those facts cannot be added together to prove a compounded mixture's clinical benefit.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
Confirm per batch COA
Formula
Not applicable — mixture or multi-component material
Molecular weight
Component-specific; no single molecular weight
Appearance
Lot-specific aqueous solution; color may vary with the cobalamin form — confirm clarity, color and particulate limits on the released-lot COA
Purity
Component-wise specification; confirm on released-lot COA · target, verify batch COA
Storage
Follow the exact product label, pharmacy or manufacturer documentation and lot-specific stability data. Cyanocobalamin is light-sensitive, while pH, preservative, container, concentration and added ingredients can change stability. Room-temperature and refrigerated instructions are not interchangeable across formulations, and a beyond-use date must not be inferred from the product name.
MOQ
1 kit (10 vials) per SKU
Lead time
Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about MIC (Lipo-C with B12)

MIC and Lipo-C are non-standardized market labels rather than one pharmaceutical composition. MIC commonly refers to methionine, inositol and choline, often with vitamin B12; Lipo-C may additionally or alternatively refer to L-carnitine-containing formulations. Concentrations, vitamin B12 form, excipients, preservatives and added prescription ingredients can differ materially. A targeted literature review did not identify a peer-reviewed clinical trial or systematic review evaluating one defined MIC/Lipo-C plus B12 injection for weight loss or general wellness. Evidence about individual nutrients, deficiency treatment or PCOS cannot establish efficacy or safety of the combination. Compounded drugs are not FDA-approved before marketing, and FDA does not pre-verify their safety, effectiveness or manufacturing quality in the same way as approved products; federal and state compounding requirements still apply. This catalogue material is research use only and not for human administration.

  • No indication is established for the combination itself
  • Component-level literature addresses nutritional reference intakes, vitamin B12 deficiency and specific inositol questions such as PCOS; it does not prove weight loss, lipolysis, wellness benefit or additive efficacy of a MIC/Lipo-C injection.

Mechanism context

The question the literature is testing

Each ingredient participates in different biochemical pathways, but a plausible component mechanism is not evidence that the injected combination causes weight loss. Choline supports phospholipid and one-carbon metabolism; methionine is an essential amino acid and methyl-group source; inositol participates in cellular signaling; vitamin B12 supports cofactor-dependent metabolism; and L-carnitine, when present, transports long-chain fatty acids into mitochondria. Formula-specific exposure, deficiency status and clinical context determine relevance.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research
Routes reported in sources
SubcutaneousIntramuscular
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Safety depends on the exact formulation, concentration, sterility assurance, route and recipient
  • No direct trial established the safety of a standardized MIC/Lipo-C plus B12 injection because no standardized product exists
  • Compounded drugs are not FDA-approved and do not undergo the same premarket review as approved medicines; this does not mean compounding is wholly unregulated
  • Ingredient-level upper intake limits and adverse effects are not a substitute for injectable-combination safety data
  • Undisclosed semaglutide, tirzepatide, phentermine or other active drugs would be a critical misbranding and safety concern
  • This catalogue material must not be administered to humans.

Interactions reported in the literature

  • A universal interaction profile cannot be assigned without a complete quantitative formula and patient context
  • Added prescription ingredients, vitamin B12 form, methionine load, choline exposure and L-carnitine presence can materially change risks
  • Evidence or warnings for one component do not automatically describe the combination, and no controlled interaction study of MIC/Lipo-C with GLP-1 medicines was located.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

MIC (Lipo-C with B12) batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

No batch COA is published for this product yet. Ask sales for the latest available document.

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

  • Qualification must begin with a complete quantitative formula: chemical form of every ingredient, concentration per millilitre, excipients, preservative, container, lot and beyond-use or expiry basis
  • Require identity and assay methods appropriate to each component, degradant and impurity controls, particulate testing, sterility and bacterial-endotoxin results for parenteral claims, container-closure integrity where applicable, and validated stability under the labelled conditions
  • A generic MIC, Lipo-B or Lipo-C label, a single CAS number, clear appearance or pharmacy-accreditation claim cannot replace batch evidence
  • Confirm that no undeclared prescription active is present.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
MIC1010 mg10 vials

Handling

Plan storage before the parcel arrives

Follow the exact product label, pharmacy or manufacturer documentation and lot-specific stability data. Cyanocobalamin is light-sensitive, while pH, preservative, container, concentration and added ingredients can change stability. Room-temperature and refrigerated instructions are not interchangeable across formulations, and a beyond-use date must not be inferred from the product name.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • No direct peer-reviewed efficacy or safety study of a standardized MIC/Lipo-C plus B12 injection was located. The Institute of Medicine choline chapter and NIH vitamin B12 fact sheet provide component background. The Cochrane review compares oral and intramuscular vitamin B12 for deficiency, not weight loss or this mixture. The 2024 inositol systematic review addresses PCOS and reports limited or uncertain evidence for several outcomes. The 2005 Cochrane version is superseded by the updated review and should not be counted as independent evidence. A telehealth article is an industry perspective, not a primary clinical source.
  1. 01

    Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (Choline chapter)

    National Academies Press (US) / NCBI Bookshelf · 1998 · authoritative nutrition science reference (Institute of Medicine dietary reference report)

    Open source
  2. 02

    Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

    Cochrane Database of Systematic Reviews · 2018 · Cochrane systematic review

    Open source
  3. 03

    Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines

    The Journal of Clinical Endocrinology & Metabolism · 2024 · systematic review and meta-analysis (used to inform international clinical guidelines)

    Open source
  4. 04

    Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (2005 original review, superseded by 2018 pub3)

    Cochrane Database of Systematic Reviews · 2005 · Cochrane systematic review (original version, historical reference only)

    Open source
  5. 05

    Vitamin B12: Fact Sheet for Health Professionals

    NIH Office of Dietary Supplements · 2025 · government health-professional fact sheet (NIH)

    Open source
  6. 06

    Lipo C and Tirzepatide: Safety and Clinical Evidence Review

    Fella Health (medical weight-loss telehealth company) · 2026 · industry/company consumer-health guide (medical weight-loss telehealth provider)

    Open source

Product FAQ

Questions buyers ask about MIC (Lipo-C with B12)

Does MIC or Lipo-C identify one standardized formula?+

No. MIC commonly means methionine, inositol and choline, often with a vitamin B12 form; Lipo-C may also refer to L-carnitine-containing or otherwise expanded mixtures. The 10 mg presentation label does not disclose the identity or amount of each component. Before ordering, obtain the complete quantitative formula per millilitre, chemical form of every component, fill volume, excipients, preservative, pH and container.

Does component-level evidence prove that a MIC/Lipo-C plus B12 mixture causes weight loss or increases energy?+

No direct peer-reviewed trial of one standardized MIC/Lipo-C plus B12 formulation was identified. Nutrient physiology, treatment of a documented deficiency, oral inositol evidence in PCOS or L-carnitine studies cannot be added together to prove efficacy, safety or synergy for a different injected mixture. NIH also notes that vitamin B12 does not increase energy in people who already obtain enough. Treat weight-loss, wellness and GLP-1-add-on claims as unverified unless supported by formula-specific controlled evidence.

What batch evidence is needed for a multi-ingredient aqueous research mixture?+

Require identity and quantitative assay for every declared component, suitable multi-analyte method validation, degradant and impurity controls, fill volume, excipient and preservative disclosure, particulates, container information and stability under the labelled conditions. If a parenteral-quality claim is made, sterility, bacterial endotoxins and container-closure integrity require separate method-qualified evidence. A generic market name, clear appearance, single CAS or total milligram label is not a batch COA.

Evidence before order

Buyer intelligence